Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma Multiforme
Latest Information Update: 02 Jan 2023
Price :
$35 *
At a glance
- Drugs Temozolomide (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Therapeutic Use
- Acronyms GCC1224
- 02 Nov 2020 Status changed from recruiting to discontinued.
- 17 May 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2024.
- 17 May 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2022.